Results 61 to 70 of about 16,301 (208)
Frontiers in Pharmacology, 2020 Subretinal fibrosis is a common pathological change that causes vision loss in neovascular age-related macular degeneration (nAMD). Treatment modalities for subretinal fibrosis are limited.
Qian Chen +11 more
doaj +1 more source
Scientific Reports, 2021 Endothelial progenitor cells (EPCs) improve endothelial impairment, which in turn restores endothelial function in patients with heart failure (HF).
Wen-Pin Huang +5 more
doaj +1 more source
Tokyo Women's Medical University Journal, 2023 Background: To compare the efficacy and safety of pemafibrate with those of fenofibrate in a real-world setting in patients with hypertriglyceridemia and type 2 diabetes (T2D).
Junko Oya +6 more
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen +3 more
wiley +1 more source
Fenofibrate activates Nrf2 through p62-dependent Keap1 degradation
, 2020 Peroxisome proliferator-activated receptor α (PPARα) activates the β-oxidation of fatty acids in the liver. Fenofibrate is a potent agonist of PPARα and is used in the treatment of hyperlipidemia.
강동훈
core +2 more sources
Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1α in db/db mice. [PDF]
PLoS ONE, 2014 Peroxisome proliferator-activated receptor (PPAR)-α, a lipid-sensing transcriptional factor, serves an important role in lipotoxicity. We evaluated whether fenofibrate has a renoprotective effect by ameliorating lipotoxicity in the kidney. Eight-week-old
Yu Ah Hong +13 more
doaj +1 more source
HIV Medicine, EarlyView.Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang +15 more
wiley +1 more source
Fenofibrate protects endothelial cells against the harmful effects of TNF-alpha
SA Heart Journal, 2017 Introduction: Fenofibrate exerts pleiotropic effects on endothelial cells (ECs) by, amongst others, increasing nitric oxide (NO) production. We aimed to investigate fenofi brate’s putative beneficial actions in healthy or TNF-alpha-induced dysfunctional ...
Westcott, Corli +6 more
doaj +1 more source
High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. [PDF]
PLoS ONE, 2011 In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit over placebo in the primary endpoint of coronary heart disease events. Increased levels of atherogenic homocysteine were observed in some patients assigned
Laxman Yetukuri +10 more
doaj +1 more source
Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.ABSTRACT The 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration‐dependent muscle toxicity, at worst rhabdomyolysis.
Ronja Levomäki +3 more
wiley +1 more source